Investigating how lymphoma cells resist treatment with PRMT5 inhibitors
Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma
This study is looking into why some people with Non-Hodgkin's lymphoma don't get better with treatments that target a specific enzyme, and it aims to find out how a protein called MUSASHI2 affects this, which could help develop better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11013353 on NIH RePORTER |
What this research studies
This research focuses on understanding why some patients with Non-Hodgkin's lymphoma do not respond to treatments targeting a specific enzyme called PRMT5. The team uses advanced techniques, including CRISPR screening, to identify genetic factors that contribute to treatment resistance. By studying both mouse models and human lymphoma cell lines, they aim to uncover the role of a protein called MUSASHI2 in lymphoma progression and treatment response. This could lead to new strategies for overcoming resistance and improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults diagnosed with Non-Hodgkin's lymphoma who have experienced treatment resistance.
Not a fit: Patients with other types of cancer or those who have not been diagnosed with Non-Hodgkin's lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with Non-Hodgkin's lymphoma, particularly those who currently experience relapses.
How similar studies have performed: Other research has shown promising results in targeting PRMT5 in various cancers, suggesting that this approach may be effective in lymphoma as well.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Kharas, Michael — Sloan-Kettering Inst Can Research
- Study coordinator: Kharas, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.